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Advances in clinical care for disorders involving any system 
of  the  body  necessitates  novel  therapeutic  strategies  that  can 
focus upon the modulation of cellular proliferation, metabolism, 
inflammation  and  longevity.  In  this  respect,  members  of  the 
mammalian forkhead transcription factors of the O class (FoxOs) 
that include FoxO1, FoxO3, FoxO4 and FoxO6 are increasingly 
being  recognized  as  exciting  prospects  for  multiple  disorders. 
These transcription factors govern  development, proliferation, 
survival  and  longevity  during  multiple  cellular  environments 
that can involve oxidative stress. Furthermore, these transcription 
factors are closely integrated with several novel signal transduc-
tion pathways, such as erythropoietin and Wnt proteins, that may 
influence the ability of FoxOs to act as a “double-edge sword” to 
sometimes promote cell survival, but at other times lead to cell 
injury. Here we discuss the fascinating but complex role of FoxOs 
during cellular injury and oxidative stress, progenitor cell devel-
opment, fertility, angiogenesis, cardiovascular function, cellular 
metabolism  and  diabetes,  cell  longevity,  immune  surveillance 
and cancer.
Introduction
Members  of  the  mammalian  forkhead  transcription  factors 
of the O class (FoxOs) that include FoxO1, FoxO3, FoxO4 and 
FoxO6 are found throughout the body and are expressed in tissues 
of the reproductive system of males and females, skeletal muscle, 
the  cardiovascular  system,  lung,  liver,  pancreas,  spleen,  thymus 
and the nervous system.1-6 Since FoxO proteins are not equally 
expressed in all tissues, it is possible that individual FoxO proteins 
may have specificity in regards to cellular function.7 For example, 
FoxO6 expression is found in several regions of the brain that 
play a significant role in cognitive function and emotion, such 
as the hippocampus, the amygdala and the nucleus accumbens.4   
In contrast, FoxO1 may be more suited for the control of motor 
function  and  memory  formation,  since  the  expression  of  this 
protein  is  primarily  in  the  striatum  and  sub-regions  of  the 
hippocampus.4 In addition, FoxO3 is more diffusely represented 
in the hippocampus, cortex and cerebellum, suggesting a comple-
mentary  role  for  this  FoxO  protein  to  control  cognitive  and 
motor function. FoxO expression can be variable in other tissues. 
Although studies in mice have shown that the mRNA distribution 
of Foxo1, Foxo3a and Foxo4 is similar in the embryo and adult,2 
Foxo1 expression was highest in adipose tissue, Foxo3a expression 
was greatest in the liver, and Foxo4 expression was strongest in 
muscle.2 Subsequent work in mice has described Foxo1 expres-
sion in all tissues with high levels in the ovaries.8 Foxo3a also was   
found  to  be  expressed  in  all  tissues  and  Foxo4  expression  was 
considered to be more tissue specific in skeletal muscle.8
Over 100 forkhead genes and 19 human subgroups that range 
from FOXA to FOXS are now known to exist since the initial 
discovery of the fly Drosophila melanogaster gene forkhead.9 The 
prior nomenclature for these proteins, such as forkhead in rhab-
domyosarcoma (FKHR), the Drosophila gene fork head (fkh), and 
Forkhead RElated ACtivator (FREAC)-1 and -2, has been replaced. 
The current nomenclature for human Fox proteins places all letters 
in uppercase, otherwise only the initial letter is listed as uppercase 
for the mouse, and for all other chordates the initial and subclass 
letters are in uppercase.10 Initially, the FoxOs were first reported in 
fusion genes in human soft-tissue tumors and leukemias. FOXO1, 
termed forkhead in rhabdomyosarcoma (FKHR), and FOXO3a, 
also  known  as  FKHRL1  (forkhead  in  rhabdomyosarcoma  like 
protein 1), and their genes were identified through chromosomal 
translocations in alveolar rhabdomyosarcoma tumors.11 The acute 
leukemia  fusion  gene  located  in  chromosome  X  (AFX),  also 
known as the FOXO4 gene, was described as a gene that fused to 
MLL transcription factor as a result of the t(X; 11) chromosomal 
translocation in acute lymphoblastic leukemia.12 A fusion between 
FOXO2 and MLL also occurs in some cases of acute myeloid 
leukemia that also is believed to be identical to FOXO3a.13
FoxO proteins function as transcription factors to either inhibit 
or activate target gene expression.14 As a result, these proteins must 
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bind to DNA through the forkhead domain that relies upon four-
teen protein-DNA contacts. The forkhead domain in Fox proteins 
consists of three α-helices, three β-sheets and two loops that are 
referred to as the wings,15 but not all winged helix domains are 
considered to be Fox proteins.16 On X-ray crystallography15 or 
nuclear  magnetic  resonance  imaging,17  the  forkhead  domain  is 
described as a “winged helix” as a result of a butterfly-like appear-
ance. High sequence homology is present in the α-helices and 
β-sheets with variations described in either absent β-sheets and 
loops or additional α-helices. Although both the first and second 
loops make contact with DNA, it is the second loop that can influ-
ence the stability of DNA binding. In addition, post-translational 
modification of FoxO proteins, such as phosphorylation or acetyla-
tion that block FoxO activity, alter the binding of the C-terminal 
basic region to DNA to prevent transcriptional activity.18 However, 
other  mechanisms  may  influence  DNA  binding  of  forkhead 
proteins, such as variations in the N-terminal region of the DNA 
recognition  helix,  changes  in  electrostatic  distribution  and  the 
ability of forkhead proteins to be shuttled to the cell nucleus.5,19
FoxO Proteins, Oxidative Stress and Cell Injury
Cellular injury that leads to apoptosis can become a significant 
component for pathology in diseases such as neurodegenerative 
disease, diabetes mellitus (DM) and cardiovascular injury.20 More 
importantly,  regulation  of  apoptotic  pathways  appears  to  serve 
a critical juncture for the control of tumor growth and unregu-
lated cell proliferation.5,21 Apoptotic cell death is considered to 
be  a  dynamic  process  that  involves  both  early  and  late  events. 
Membrane  phosphatidylserine  (PS)  externalization  is  an  early 
event  during  cell  apoptosis  that  assists  microglia  to  target  cells 
for  phagocytosis.22,23  This  process  occurs  with  the  expression 
of  the  phosphatidylserine  receptor  (PSR)  on  microglia  during 
oxidative stress,24-26 since blockade of PSR function in microglia 
prevents  the  activation  of  microglia.27,28  As  an  example,  exter-
nalization of membrane PS residues occur in cells during periods 
of oxidative stress that involve anoxia,29 reactive oxygen species 
(ROS)  exposure30  and  with  agents  that  produce  ROS,  such  as 
6-hydroxydopamine.31 In contrast to cells with PS exposure, the 
cleavage of genomic DNA into fragments is considered to be a 
later  event  during  apoptotic  injury.20,32  Endonucleases  respon-
sible for DNA degradation have been identified and include the 
acidic,  cation  independent  endonuclease  (DNase  II),  cyclophi-
lins,  and  the  97  kDa  magnesium—dependent  endonuclease. 
In  the  nervous  system,  endonucleases  include  a  constitutive 
acidic cation-independent endonuclease, a constitutive calcium/
magnesium-dependent endonuclease and an inducible magnesium 
dependent endonuclease.20,32
Interestingly, the induction of apoptosis in cells through FoxO 
proteins  may  require  pathways  aligned  with  oxidative  stress. 
Oxidative stress is a result of the release of reactive oxygen species 
(ROS)  that  consist  of  oxygen  free  radicals  and  other  chemical 
entities. Oxygen free radicals and mitochondrial DNA mutations 
have become associated with tissue injury, aging and accumulated 
toxicity for an organism.20 ROS include superoxide free radicals, 
hydrogen peroxide, singlet oxygen, nitric oxide and peroxynitrite.32 
Most reactive species are produced at low levels during normal 
physiological conditions and are scavenged by endogenous anti-
oxidant  systems  that  include  superoxide  dismutase,  glutathione 
peroxidase, catalase and small molecules, such as vitamins C, E,   
D3  and  nicotinamide,  the  amide  form  of  niacin  or  vitamin 
B3.23,33,34  During  periods  of  oxidative  stress,  FoxO  transcrip-
tion factors can lead to apoptosis,35 since forkhead transcription 
factors such as FoxO1 and FoxO3a must be present for oxidative 
stress to result in apoptotic cell injury.36 Under other conditions 
of oxidative stress, FoxO3a in conjunction with JNK have been 
shown to modulate an apoptotic ligand activating a Fas-mediated 
death pathway in cultured motoneurons,37 to lead to apoptosis 
through  tumor-necrosis-factor-related  apoptosis-inducing  ligand 
(TRAIL) and BH3-only proteins Noxa and Bim in neuroblastoma 
cells,38 and to promote pro-apoptotic activity of p53.39 Additional 
work shows that loss of FoxO expression during oxidative stress is   
protective to cells. For example, protein inhibition or gene knock-
down  of  FoxO1  or  FoxO3a  can  lead  to  reduction  in  ischemic 
infarct  size  in  the  brain,40  mediate  protection  of  metabotropic 
glutamate receptors during vascular injury,41 enhance pancreatic 
β-cell  or  neuronal  survival  through  NAD+  precursors  during 
oxidative  stress42  and  provide  trophic  factor  protection  with 
erythropoietin  (EPO)43  and  neurotrophins.44  Yet,  it  should  be 
noted that some studies suggest that the loss of FoxO1, FoxO3a 
and FoxO4 protein expression may actually lead to an increase in 
free radical release that can be responsible for oxidative stress.45   
In addition, FoxO proteins may be protective during aging and 
exercise,  since  FoxO3a  activity  may  enhance  vascular  smooth 
muscle antioxidant properties in aged animals and be beneficial to 
the cardiovascular system during physical exertion.46
FoxO Proteins and Progenitor Cells
The initial identification of FoxO proteins in soft-tissue tumors 
and  leukemias,  neoplasms  now  believed  to  harbor  cancer  stem 
cells for tumor self-renewal,47 suggests that FoxO proteins may 
be closely associated with the oversight of stem cell proliferation 
and  differentiation.  For  example,  either  simultaneous  deletion 
of Foxo1, Foxo3a and Foxo4 or single deletion of Foxo3a in mice 
prevents the repopulation of hematopoietic stem cells and leads 
to  apoptosis  in  these  stem  cell  populations.45,48  Furthermore, 
vascular cytoprotective agents, such as the growth factor EPO,49-51 
also may be required to modulate FoxO protein activity such as 
during  erythroid  progenitor  cell  development,52,53  suggesting 
that current clinical use of agents such as EPO during anemia or 
cancer may have less defined treatment implications for patients 
than originally anticipated.51,53 In cell culture and animal studies, 
EPO is cytoprotective in vascular cells and can stimulate postnatal 
neovascularization by increasing endothelial progenitor cell mobi-
lization from the bone marrow.52-54 Interestingly, the ability of 
EPO to foster eythroid progenitor cell development is dependent 
upon the inhibition of FoxO3a activity,51,53 but also may require 
regulation of specific gene expression through an EPO-FoxO3a 
association to promote erythropoiesis in cultured cells.55 In relation 
to  the  reproductive  potential  of  an  organism,  deletion  of  the 
FoxO3a gene results in the depletion of oocytes and subsequent 
infertility.56
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In light of the ability of FoxO proteins to regulate vascular 
smooth muscle cell proliferation, these transcription factors may 
have a significant clinical role in regards to disorders that involve 
hypertension and cardiac failure. Vascular smooth muscle cells are 
vital for the regulation of vascular tone and systemic arterial blood 
pressure. For example, high flow states in vessels can reduce FoxO1 
activity, resulting in the potential proliferation of vascular smooth 
muscle  cells,  vascular  neointimal  hyperplasia  and  subsequent 
pathological states such as hypertension.67 In fact, α1-adrenergic 
agonists that increase systemic blood pressure can have the reverse 
effect  and  stimulate  the  expression  of  FoxO1  and  its  nuclear 
translocation  that  ultimately  may  lead  to  apoptotic  endothelial 
cell  injury.68  In  addition,  more  than  moderate  levels  of  vessel 
cyclic stretch that can occur during hypertension may lead to the   
phosphorylation and inhibition of Foxo1 and Foxo3a in smooth 
muscle cells to further contribute to pathological smooth muscle 
cell  proliferation.69  Furthermore,  in  human  as  well  as  murine 
models of cardiac failure, increased expression of Fox transcription 
factors, such as FoxO1a, have been observed to suggest a potential 
association of FoxO proteins with imminent cardiac failure.70
FoxO Proteins and Regulation of Immunity
Forkhead  transcription  factors  have  an  important  role  in 
maintaining immune system function. For example, the forkhead 
family member FoxP3 can control the development and function 
of thymic-derived CD4(+)CD25(+) regulatory T cells (Treg) that 
impart autoimmunity. Loss of FoxP3 can result in autoimmune 
disorders.71 In addition, recent work identifies the expression of 
FoxP3 in tumor cells, such as melanoma,72 as well as in Tregs 
which may significantly affect patient mortality since the increased 
presence of Tregs in cancer patients combined with FoxP3 expres-
sion in tumors may impair antitumor autoimmune responses and 
lead to high mortality.73
In regards to FoxO proteins, these forkhead transcription factors 
also may influence early apoptotic membrane PS externalization. 
The ability to regulate early apoptotic membrane PS exposure27 
and inflammatory cell activity22 can ultimately affect cell survival 
since activated immune cells can lead to the phagocytic removal 
of tumor cells.24,32 Inflammatory cells, such as macrophages or 
microglia,  require  the  activation  of  intracellular  cytoprotective 
pathways to proliferate and remove injured cells.25,74 At times, 
this can be a beneficial process and form a barrier for the removal 
of foreign microorganisms and promote tissue repair during cell 
injury.33,52 However, inflammatory cells also may lead to cellular 
damage through the generation of ROS and through the produc-
tion  of  cytokines.52  Interestingly,  in  mice  deficient  for  Foxo3a, 
lymphoproliferation, organ inflammation of the salivary glands, 
lung and kidney, and increased activity of helper T cells results, 
supporting  an  important  role  for  FoxO3a  in  preventing T  cell 
hyperactivity.75 FoxO3a also appears to be necessary for neutrophil 
activity, since Foxo3a null mice are resistant to models of neutro-
philic  inflammation  that  involve  immune  complex-mediated 
inflammatory arthritis.76
In  clinical  studies,  patients  with  rheumatoid  arthritis  and 
osteoarthritis show phosphorylation of FOXO3a in T lympho-
cytes as well as FOXO1 and FOXO4 in synovial macrophages, 
Other work using a mouse model of FoxO3a overexpression in 
oocytes further suggests that FoxO3a retards oocyte growth and 
follicular development and leads to anovulation and luteinization 
of  unruptured  follicles.57 These  studies  may  suggest  a  role  for 
FoxO proteins, and specifically FoxO3a, in relation to not only 
the development of cancer stem cell niches, but also in regards 
to oocyte and follicular cell maturation. For example, in a small 
percentage of women who suffer from premature ovarian failure 
mutations in FOXO3a and FOXO1a have been observed.58
FoxO Proteins, Angiogenesis, Cardiovascular Function  
and Vascular Tone
FoxO proteins also play a significant role to control new vessel 
growth that can impact upon cardiovascular development. New 
capillary formation from pre-existing vessels into an avascular area 
is a process known as angiogenesis that is present during embryo-
genesis,  during  menstruation  and  during  pathological  processes 
that  involve  wound  healing,  chronic  inflammation  and  tumor 
growth.53,59 FoxO proteins are intimately involved in endothelial 
cell  development  and  angiogenesis.  For  example,  Foxo3a-/-  and 
Foxo4-/- mice develop without incidence and are indistinguishable 
from control littermates. However, mice that are singly deficient 
in Foxo1 die by embryonic day eleven and lack development of 
the vascular system.60 Additional studies illustrate that endothelial 
cell colonies in Foxo1-deficient mice fail to respond to vascular 
endothelial  growth  factor  in  a  manner  similar  to  wild-type 
endothelial  cells,61  suggesting  that  FoxOs  are  necessary  for  the 
development of vascular cells as well as for the biological response 
to cellular mediators.
During cardiac development, FoxO proteins also appear to be 
necessary to modulate cardiomyocyte proliferation. Both FoxO1 
and  FoxO3  are  expressed  during  embryonic  through  prenatal 
stages  in  the  developing  myocardium. The  expression  of  these 
FoxO  proteins  is  believed  to  negatively  regulate  cardiomyocyte 
growth,  since  overexpression  of  FoxO1  blocks  cardiomyocyte 
proliferation  but  expression  of  dominant  negative  FoxO1  leads 
to  enhanced  cardiomyocyte  growth.62  These  observations  may 
provide clues into the roles of FoxO proteins during cardiac hyper-
trophy. Atrogin-1, a protein that can block cardiac hypertrophy, 
may rely upon the upregulation of Foxo1 and Foxo3a to disrupt 
cardiac hypertrophy, since mice lacking atrogin-1 are susceptible 
to cardiac hypertrophy and do not yield increased expression of 
Foxo1 and Foxo3a.63
In  regards  to  smooth  muscle  cell  growth,  Foxo3a  has  been 
demonstrated to block vascular smooth muscle proliferation and may 
lessen the effects from disorders such as atherosclerosis and hyperten-
sion. In a rat balloon carotid arterial injury model, gene transfer of 
FoxO3a can inhibit neointimal hyperplasia through the prevention 
of vascular smooth muscle growth.64 However, not all FoxO proteins 
may exert an inhibitory effect upon vascular smooth muscle cells. 
FoxO4 may inhibit smooth muscle cell differentiation through the 
repression of the transcriptional coactivator of smooth muscle genes 
myocardin,65 but other work suggests that FoxO4 also can increase 
matrix metalloproteinase 9 expression to promote vascular smooth 
muscle migration and foster neointimal hyperplasia.66122 Oxidative Medicine and Cellular Longevity 2009; Vol. 2 Issue 3
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insulin signaling and lead to lifespan extension,87,88 suggesting a 
significant role for FoxO proteins in relation to mammalian cell 
function.5,11 In fact, FoxO proteins can stimulate the insulin-like 
growth factor binding protein-1 (IGFBP1) promoter by binding to 
the insulin-responsive sequence (IRS).89 Both insulin and insulin-
like growth factor-1 (IGF-1) can suppress this activity through 
activation of Akt.89,90
In clinical studies, analysis of the genetic variance in FOXO1a 
and FOXO3a on metabolic profiles, age-related diseases, fertility, 
fecundity  and  mortality  have  observed  higher  HbA1c  levels 
and  increased  mortality  risk  associated  with  specific  haplotypes 
of  FOXO1a.91  These  clinical  observations  may  coincide  with 
the  demonstration  in  human  endothelial  progenitor  cells  that 
elevated glucose levels can reduce post-translational phosphoryla-
tion of FOXO1, FOXO3a and FOXO4 and allow for the nuclear 
translocation of these proteins to initiate an apoptotic program 
in endothelial progenitor cells.92 In experimental models, FoxO 
proteins may prevent the toxic effects of high serum glucose levels. 
Interferon-gamma driven expression of tryptophan catabolism by 
cytotoxic T lymphocyte antigen 4 may activate Foxo3a to protect 
dendritic cells from injury in nonobese diabetic mice.93 Additional 
studies have demonstrated that adipose tissue-specific expression 
of Foxo1 in mice improved glucose tolerance and sensitivity to 
insulin  during  an  elevated  fat  diet.94  FoxO  proteins  also  may 
protect  against  diminished  mitochondrial  energy  levels  known 
to occur during insulin resistance such as in the elderly popula-
tions.33,82,83 In caloric restricted mice that have decreased energy 
reserves, Foxo1, Foxo3a and Foxo4 mRNA levels were noted to 
progressively increase over a two year course.3 These observations 
complement  studies  in  Drosophila  and  mammalian  cells  that 
demonstrate an increase in insulin signaling to regulate cellular 
metabolism during the upregulation of FoxO1 expression.95
However,  the  ability  for  FoxO  proteins  to  maintain  proper 
physiologic controls over cellular metabolism may be limited and 
occur only during specific circumstances. For example, mice with 
a constitutively active Foxo1 transgene have increased microsomal 
triglyceride  transfer  protein  and  elevated  plasma  triglyceride 
levels.96 Studies in cardiomyocytes also suggest detrimental results 
with enhanced FoxO activity. Increased transcriptional activity of 
FoxO1, such as by the Sirt1 activator resveratrol, can diminish 
insulin mediated glucose uptake and result in insulin resistance.97 
In addition, overexpression of Foxo1 in skeletal muscles of mice 
can  lead  to  reduced  skeletal  muscle  mass  and  poor  glycemic 
control,98 illustrating that activation of FoxO proteins also may 
impair cellular energy reserves. Additional investigations that block 
the expression of Foxo1 in normal and cachectic mice99 or reduce 
FoxO3 expression100 show the reverse with an increase in skeletal 
muscle mass or resistance to muscle atrophy. These results become 
especially relevant in patients with cancer and cachexia, since FoxO 
protein expression may further muscle wasting for these individuals.   
Given  these  concerns,  one  potential  agent  to  consider  for  the 
maintenance of cellular metabolism in cancer patients is nicotin-
amide,23,101 an agent that also can inhibit FoxO protein activity.42 
In patients with DM, oral nicotinamide protects β-cell function, 
prevents clinical disease in islet-cell antibody-positive first-degree 
relatives  of  type-1  DM,  and  can  reduce  HbA1c  levels.23,82,101 
suggesting that loss of functional FOXO family members may lead 
to inflammatory cell activation in these disorders.77 FOXO1 gene 
transcript levels also are downregulated in peripheral blood mono-
nuclear cells of patients with systemic lupus erythematosus and 
rheumatoid arthritis,78 illustrating a potential etiology through the 
loss of functional FOXO proteins for these disorders and possibly 
providing a biomarker of disease activity. Other work has demon-
strated that FOXO1 protein regulates L-selectin expression that 
can regulate human T lymphocyte trafficking.79 More importantly, 
studies suggest a relationship between the regulation of immune 
system  activity  and  the  induction  of  apoptotic  pathways  that 
are dependent upon FoxO proteins. Prevention of inflammatory 
activation and apoptosis in the nervous system such as in systemic 
lupus erythematosus in animal models may require the upregula-
tion of different Fox proteins, such as FoxJ1 and FoxO3a, that 
can  block  NFκB  activation  and  interferon-gamma  secretion.80 
FoxO proteins also may work in concert with Fas signaling to 
clear activated T cells following a decrease in cytokine stimulation 
in  patients  with  autoimmune  lymphoproliferative  syndromes,81 
suggesting that activation of specific FoxO proteins may be benefi-
cial for autoimmune disorders but may impair treatments designed 
to target tumor cells through immune mediated pathways.
FoxO Proteins, Diabetes and Modulation of Cellular 
Metabolism
DM represents a significant health concern for both young and 
older populations.82,83 Approximately 16 million individuals in the 
US and more than 165 million individuals worldwide suffer from 
DM. By the year 2030, it is predicted that more than 360 million 
individuals will be afflicted with DM and its debilitating condi-
tions. Type 2 DM represents at least 80 percent of all diabetics 
and is dramatically increasing in incidence as a result of changes 
in human behavior and increased body mass index.33,82 Type 1 
insulin-dependent DM is present in 5–10 percent of all diabetics, 
but is increasing in adolescent minority groups.33,82 Furthermore, 
the incidence of undiagnosed diabetes and impaired glucose toler-
ance in the population raises additional concerns.
Patients  with  DM  can  develop  significant  neurodegener-
ative33,84,85  and  cardiovascular  disease.33,86  Interestingly,  the 
development of insulin resistance and the complications of DM 
can be the result of cellular oxidative stress.33,82 Hyperglycemia can 
lead to increased production of ROS in endothelial cells, liver cells 
and  pancreatic  β-cells.33,82,83  Recent  clinical  correlates  support 
these experimental studies to show that elevated levels of ceru-
loplasmin are suggestive of increased ROS.33,82,83 Furthermore, 
acute  glucose  swings  in  addition  to  chronic  hyperglycemia  can 
trigger  oxidative  stress  mechanisms,  illustrating  the  importance 
for therapeutic interventions during acute and sustained hyperg-
lycemic episodes.33,82
Early  work  with  FoxO  proteins  has  shown  that  metabolic 
signaling  with  these  transcription  factors  is  conserved  among 
multiple  species  including  Caenorhabditis  elegans,  Drosophila 
melanogaster  and  mammals.  FoxO  proteins  are  homologous 
to  the  transcription  factor  DAuer  Formation-16  (DAF-16)  in 
the  worm  Caenorhabditis  elegans  that  can  determine  metabolic www.landesbioscience.com Oxidative Medicine and Cellular Longevity 123
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in light of the ability of FoxO proteins to lead to apoptosis and 
block cell cycle progression. For example, FoxO3a and FoxO4 can 
promote cell cycle arrest in mouse myoblastic cell lines through 
modulation of growth-arrest and DNA-damage-response protein 
45.5,52 Treatment of chronic myelogenous leukemia cell lines with 
the Bcr-Abl tyrosine kinase inhibitor imatinib requires FoxO3a 
activation to antagonize cell proliferation and promote apoptotic 
cell death through increased TRAIL production.113 In addition, 
the transcription factor E2F-1 that controls the induction of the 
cell cycle has been reported in cell lines to increase the endogenous 
expression of FoxO1 and FoxO3a to lead to cell cycle arrest.114 In 
contrast, the loss of FoxO3a activity in association with c-myc, p27 
and nuclear factor-κB (NFκB) can result in cell cycle induction 
and malignant transformation of mouse cells in the presence of 
oncogene activation.5,11 Other work suggests that FoxO proteins 
utilize the p53 upstream regulator p19(Arf) through myc to block 
cell cycle induction and lymphoma progression.115
In  regards  to  cancer  cell  progression,  studies  with  prostate 
cancer have shown that the tumor suppressor phosphatase and 
tensin homolog deleted on chromosome ten (PTEN) is mutated 
in approximately eighty percent of tumors with the loss of FOXO1 
and FOXO3a activity. In cell cultures, overexpression of FoxO1 
and FoxO3a in prostrate tumor cell lines also leads to apoptosis, 
suggesting  that  FoxO1  and  FoxO3a  are  necessary  for  limiting 
prostate cell tumor growth.6 In addition, it has been shown that 
inhibition  of  FoxO3a  activity  can  result  in  enhanced  prostate 
tumor cell growth116 while agents that increase FoxO3a activity 
in both androgen sensitive and androgen insensitive prostate cell 
lines  prevent  prostate  cancer  cell  progression.117  Furthermore, 
therapeutic strategies that rely upon the overexpression of a non-
phosphorylatable form of FoxO3a that cannot be inactivated can 
sensitize  prostate  cancer  cells  to  androgen-withdrawal-induced 
apoptosis.118 However, it should be noted that in prostate cell lines 
FoxO3a can be a positive regulator of androgen receptor expres-
sion and therefore may play a complex role in prostate cancer cell 
proliferation and growth inhibition.119 Other factors that control 
FoxO protein function also may play a role during prostate tumor 
progression.  In  prostate  cancer  cells,  cyclin-dependent  kinase  1 
(CDK1) can become overexpressed and subsequently phosphory-
late FOXO1 to block its transcriptional activity and contribute to 
prostate tumorigenesis.120 In a similar manner, it has been shown 
that  astrocyte-elevated  gene-1  (AEG-1)  can  be  upregulated  in 
clinical prostate cancer,121 possibly lead to activation of Akt that 
suppresses FOXO3a122 and apoptosis in prostate tumor cells.
Initial  investigations  of  FOXO3a  in  clinical  breast  cancer 
suggested that activation of FOXO3a was associated with lymph 
nodal  metastasis  and  a  poor  prognosis.123  In  contrast  to  these   
observations, other studies reported that FOXO3a was inactivated 
by IKK and that inactivation of FOXO3a was associated with a   
poor  prognosis  in  breast  cancer,124  suggesting  that  FOXO3a   
sub-cellular  localization  and  pathways  that  enhance  its  activity 
could  be  used  not  only  as  prognostic  assays  but  also  as  thera-
peutic targets. Other work in breast cancer cells demonstrate the 
tumor  repressive  ability  of  FoxOs  by  illustrating  that  increased 
activity of FoxO3a in association with JNK in breast cancer cell 
lines125 or in association with cyclin-dependent kinase inhibitor 
Nicotinamide,  which  is  closely  linked  to  cell  longevity  path-
ways,102,103  may  derive  its  protective  capacity  through  two 
separate mechanisms of post-translational modification of FoxO3a. 
Nicotinamide not only can maintain phosphorylation of FoxO3a 
and  inhibit  its  activity,  but  also  can  preserve  the  integrity  of   
the FoxO3a protein to block FoxO3a proteolysis that can yield 
pro-apoptotic amino-terminal fragments.42
FoxO Proteins, Aging and Longevity
FoxO proteins also have been associated with cell longevity and 
aging as shown by early studies linking DAF-16 in Caenorhabditis 
elegans  to  increased  longevity.11,104-106  However,  the  relationship 
between  FoxO  transcription  factors  and  proteins  that  increased 
cellular lifespan has been met with controversy. Sirt1 is a NAD+-
dependent deacetylase and the mammalian ortholog of the silent 
information  regulator  2  (Sir2)  protein  associated  with  increased 
lifespan  in  yeast.  Some  studies  suggest  that  stimulation  of  Sirt1 
during  starvation  is  dependent  upon  FoxO3a  activity  as  well  as 
p53.107  In  contrast,  other  work  has  shown  in  cell  culture  that   
Sirt1  may  repress  the  activity  of  FoxO1,  FoxO3a  and  FoxO4, 
suggesting  that  cellular  longevity  may  benefit  from  reduction  in 
FoxO  protein  generated  apoptosis.108  Additional  studies  offer 
alternative  views  to  illustrate  that  Sirt1  binds  to  FoxO  proteins, 
such as FoxO4, to catalyze its deacetylation and enhance FoxO4 
activity  while  acetylation  of  FoxO4  by  cyclic-AMP  responsive 
element binding (CREB)-binding protein serves to inhibit FoxO4   
transcriptional activity.11,104-106
FoxO proteins may be protective during aging, cell senescence 
and exercise. In cultured human dermal fibroblasts, gene silencing 
of FoxO3a protein results in cell morphology consistent with cell 
senescence,  cell  population  doubling  times,  and  the  generation 
of ROS, suggesting that FoxO protein activity may be required 
to extend cell longevity and limit oxidative stress.109 Additional 
work in animal models of aging demonstrates a reduction in Sirt1 
in the heart, but no significant change in FoxO3a expression with 
advanced age. However, during exercise training, an upregulation 
of FoxO3a and Sirt1 activity is observed in the heart,46 suggesting 
that the benefits of physical activity for the cardiovascular system 
may  be  associated  with  FoxO  proteins.  Interestingly,  increased 
levels of Sirt1 less than 7.5-fold can be associated with expres-
sion of catalase, an anti-oxidant that is controlled by FoxO1a to 
possibly reduce cell injury during oxidative stress. Yet, elevated 
levels of Sirt1 at 12.5-fold can result in cardiomyocyte apoptosis 
and  decreased  cardiac  function.110  In  addition,  FoxO  proteins 
may be protective during aging, since loss of FoxO3a activity in 
explanted vascular smooth muscle of aged animals may limit tissue 
antioxidant properties through decreased manganese superoxide 
dismutase  and  lead  to  enhanced  cell  injury  with  aging.111 
Extension of cellular lifespan that depends upon the prevention 
of cell senescence at least in primary human cultured vascular cells 
also may require the negative regulation of Akt to allow for the 
activation of FoxO3a.112
FoxO Proteins and Uncontrolled Cell Growth
FoxO proteins represent important targets for several disorders. 
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Modulation of Akt activity also oversees apoptotic pathways of 
caspases that may offer an alternative mechanism to regulate FoxO 
proteins 142 (Fig. 1). Caspases are a family of cysteine proteases that 
are synthesized as inactive zymogens that are proteolytically cleaved 
into subunits at the onset of apoptosis.101,143,144 The caspases 1 
and 3 have been linked to the apoptotic pathways of genomic DNA 
cleavage, cellular membrane PS exposure and activation of inflam-
matory cells.27,145,146 Caspase pathways may be tied to the forkhead 
transcription  factor  FoxO3a  since  increased  activity  of  FoxO3a 
can result in cytochrome c release and caspase-induced apoptotic 
death.38,41-43 Pathways that can inhibit caspase 3 activity appear to 
offer a unique regulatory mechanism (Fig. 1). For example, recent 
work suggests that cell death pathways that rely upon FoxO3a also 
appear to involve caspase 3 activation.147 Prior studies suggest that 
not only does FoxO3a activity promote caspase-induced apoptotic 
death,38,41-43  but  also  demonstrate  that  inhibition  of  caspase  3 
has been shown to maintain the phosphorylated “inactive” state 
of FoxO3a to prevent cell injury.41-43 Other work has shown that 
caspase 3 activity and cleavage is promoted during transfection of 
a triple mutant FoxO3a expression in which three phosphorylation 
sites have been altered to prevent inactivation of FoxO3a.148 Recent 
work adds further insight to these studies by illustrating that FoxO3a 
may control early activation and subsequent apoptotic injury in 
microglia  during  amyloid  (Aβ)  exposure  through  caspase  3.147 
Since Aβ exposure can facilitate the cellular trafficking of FoxO3a 
from the cytoplasm to the cell nucleus to potentially lead to “pro-
apoptotic” programs by this transcription factor,147 one program 
p27  in  isolated  human  breast  cancer  cells  can 
prevent  breast  cancer  growth.126  In  addition, 
FoxO proteins may be able to modulate estrogen 
function  and  indirectly  block  breast  cancer 
growth.  Overexpression  of  FoxO3a  in  breast 
cancer cell lines can decrease the expression of 
estrogen  receptor  regulated  genes  and  inhibits 
17beta-estradiol  (E2)-dependent  breast  cancer 
growth.127
In addition to the ability to inhibit prostate 
and  breast  tumor  growth,  FoxO  proteins  may 
represent  a  viable  option  to  control  tumor 
progression  in  other  tissues.  FoxO  proteins 
can function as redundant repressors of tumor 
growth. For example, somatic deletion in mice of 
Foxo1, Foxo3a and Foxo4 results in the growth of 
thymic lymphomas and hemangiomas.128 Other 
work illustrates that FoxO3a activation in colon 
carcinoma  cell  lines  prevents  tumor  prolifera-
tion through Myc target genes that involve the 
Mad/Mxd family of transcriptional repressors.129   
In  addition,  the  loss  of  FoxO3a  activity  may 
participate  in  oncogenic  transformation  in 
B-chronic lymphocytic leukemia130 and in the 
progression  of  chronic  myelogenous  leukemia 
cell  lines.113  Furthermore,  studies  suggest  that 
some  proteins,  such  as  the  Kaposi’s  sarcoma-
associated  herpes  virus  latent  protein  LANA2, 
may specifically block the transcriptional activity of FoxO3a to 
lead to tumor growth.131 In cell models of endometrial cancer, 
pre-sensitization of cells to block Akt activation and foster tran-
scription activity of FoxO1 enhances the effect of chemotherapy 
to limit tumor growth.132
FoxO Proteins and Post-Translational Pathways
Post-translational  modulation  of  FoxO  proteins  involves 
pathways associated with phosphorylation, acetylation and ubiqui-
tylation.5,11,104,106,133 The serine-threonine kinase protein kinase 
B  (Akt)  is  a  primary  mediator  of  phosphorylation  of  FoxO1, 
FoxO3a and FoxO4 that can block activity of these proteins.11,134 
Activation  of  Akt  is  usually  cytoprotective,  such  as  during 
hyperglycemia,135 hypoxia,136 β-amyloid (Aβ) toxicity,137 cardio-
myopathy,138 cellular aging139 and oxidative stress.22,28,140 Akt can 
prevent cellular apoptosis through the phosphorylation of FoxO 
proteins.35  Post-translational  phosphorylation  of  FoxO  proteins 
will  maintain  FoxO  transcription  factors  in  the  cytoplasm  by 
association with 14-3-3 proteins and prevent the transcription of 
pro-apoptotic target genes.43,51 An exception to these observations 
involving  the  subcellular  trafficking  of  FoxO  proteins  involves 
FoxO6. This FoxO protein usually resides in the nucleus of cells 
and is phosphorylated by Akt in the nucleus. FoxO6 does not 
contain a conserved C-terminal Akt motif which limits nuclear 
shuttling of this protein, but FoxO6 transcriptional activity can   
be  blocked  by  growth  factors  independent  of  shuttling  to  the 
cytosol through a FoxO6 N-terminal Akt site.141
Figure 1. Gene silencing of FoxO3a prevents activation of caspase 3 in endothelial cells 
(ECs)  following  oxygen  glucose  deprivation  (OGD).  ECs  were  transfected  with  FoxO3a 
siRNA for 3 days and the cells were then subjected to OGD for an 8-hour period of time. 
Immunofluorescent staining for active caspase 3 was performed 6 hours following an 8hour 
period of OGD by using primary rabbit antibody against active caspase 3 and visualized 
by  Texas-red  labeled  anti-rabbit  antibody.  Nuclei  of  ECs  were  counterstained  with  DAPI.   
In merged images, cells with OGD alone show ECs with significant caspase 3 staining (red).   
In  contrast,  active  caspase  3  staining  was  significantly  reduced  during  gene  silencing  of 
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in relation to Alzheimer disease, Aβ is toxic to cells29,137 and is   
associated with the phosphorylation of FoxO1 and FoxO3a that   
can be blocked with ROS scavengers.157 A common denominator   
in  the  pathways  linked  to  Aβ  toxicity  involves  Wnt  signaling 
through β-catenin. β-catenin may increase FoxO transcriptional 
activity and competitively limit β-catenin interactionwith members 
of  the  lymphoid  enhancer  factor/T  cell  factor  family158  and 
β-catenin also has been demonstrated to be necessary for protec-
tion against Aβ toxicity in neuronal cells.29
Additional shared signal transduction pathways between Wnt 
and  FoxO  proteins  involve  Akt.  Processes  that  involve  cellular 
proliferation, injury and immune system modulation with FoxO 
proteins159 also have parallel cellular pathways with Wnt and Akt. 
For example, Wnt relies upon Akt for the proliferation and differen-
tiation of cardiomyocytes.160 In addition, reduction in tissue injury 
during pressure overload cardiac hypertrophy and the cytoprotective 
benefits of cardiac ischemic preconditioning also appear to depend 
upon  Akt.59,155  Furthermore,  Wnt  overexpression  can  indepen-
dently increase the phosphorylation and the activation of Akt to 
promote cellular protection and control microglial activation.29
Yet, other members of the forkhead family in addition to FoxOs 
also rely upon Wnt signaling in several scenarios that involve regu-
lated as well as unchecked cell proliferation.59,155,161 For example, 
FoxD3 is activated by the Wnt pathway to control neural plate 
development162 and Foxl1 activates the Wnt/β-catenin pathway 
to  increase  extracellular  proteoglycans,  promote  gastrointestinal 
cell proliferation, and possibly foster carcinogenesis.163 The Wnt 
pathway also utilizes forkhead members to modulate endocrine 
activity and can activate Foxn1 for regulatory control of thymic 
function.164 In other examples of cell development, Wnt signaling 
has been shown to rely upon Foxf1 and Foxf2 during intestinal 
maturation  in  murine  models.165  In  addition,  Foxa2  in  mice 
may be a significant component in early anterior-posterior axis 
polarization.166 Deregulation of Wnt alone also promotes activa-
tion of β-catenin that has been associated with the proliferation 
of  medulloblastoma  tumors.47  In  addition,  reduced  expression 
of inhibitors of the Wnt pathway, such as axin, may foster lung 
cancer cell invasion.167 Multiple other studies also point to the 
activation of the Wnt pathway during gastric cancer. For example, 
Wnt5a expression has been correlated with advanced gastric cancer 
stages and a poor prognosis168 while experimental activation of the 
β-catenin pathway leads to the development of gastric tumors.169 
In  conjunction  with  forkhead  proteins,  loss  of  Foxl1  that  can 
regulate the Wnt pathway and prevent β-catenin nuclear accumu-
lation is believed to be a significant etiology for gastrointestinal 
tumorigenesis.163
Future Perspectives
FoxO proteins represent unique and exciting cellular targets 
that can control numerous processes such as angiogenesis, cardio-
vascular  development,  vascular  tone,  oxidative  stress,  stem  cell 
proliferation,  fertility,  immunity  and  cancer.  In  relation  to  the 
treatment of cancer, the ability of FoxO proteins to control cell 
cycle progression and promote apoptosis illustrates the potential 
of FoxOs to become an important component for new strategies 
in  particular  that  may  be  vital  for  apoptotic  injury  appears  to 
involve the activation of caspase 3. Aβ exposure leads to a rapid and 
significant increases in caspase 3 activity with six hours following 
Aβ administration, but that this induction of caspase 3 activity by 
Aβ requires FoxO3a, since loss of FoxO3a through gene silencing 
prevents the induction of caspase 3 activity by Aβ.
Post-translational modulation of FoxO proteins also requires 
pathways associated with ubiquitylation and acetylation.149,150 Akt 
phosphorylation of FoxO proteins not only retains these transcrip-
tion factors in the cytoplasm, but also leads to ubiquitination and 
degradation through the 26S proteasome.104,150 In the absence of 
Akt, IκB kinase (IKK) also can directly phosphorylate and block 
the  activity  of  FoxO  proteins,  such  as  FoxO3a.5,11  This  leads 
to the proteolysis of FoxO3a via the Ub-dependent proteasome 
pathway.5,11,104,106,133 The  serum-  and  glucocorticoid-inducible 
protein  kinase  (Sgk),  a  member  of  a  family  of  kinases  termed 
AGC (protein kinase A/protein kinase G/protein kinase C) kinases 
which includes Akt, also can phosphorylate and retain FoxO3a in 
the cytoplasm.151 Knowledge that Sgk and Akt can phosphorylate 
FoxO3a at different sites may offer new opportunities to more 
effectively prevent apoptotic cell injury that may be mediated by 
FoxO3a activity. Yet, phosphorylation of FoxO proteins does not 
always lead to negative regulation. The protein kinase mammalian 
sterile  20-like  kinase-1  also  can  phosphorylate  FoxO  proteins 
directly  and  lead  to  their  activation.152  The  ability  of  sterile 
20-like kinase-1 to activate FoxO proteins may be linked to c-Jun 
N-terminal kinase (JNK), since sterile 20-like kinase-1 can increase 
JNK activation.153 FoxO proteins also are acetylated by histone 
acetyltransferases that include p300, the CREB-binding protein 
(CBP),  and  the  CBP-associated  factor  and  are  deacetylated  by 
histone deacetylases, such as Sirt1, a NAD+-dependent deacetylase 
and the mammalian ortholog of the silent information regulator 2 
(Sir2)  protein.5  Acetylation  of  FoxO  proteins  provides  another 
avenue for the control of these proteins. Once acetylated such as 
by CBP, FoxO proteins may translocate to the cell nucleus but   
have  diminished  activity  since  acetylation  of  lysine  residues  on 
FoxO  proteins  has  been  shown  to  limit  the  ability  of  FoxO 
proteins to bind to DNA.154 In addition, acetylation can increase 
phosphorylation of FoxO proteins by Akt.154
FoxO Proteins and Unique Signaling Pathways
FoxO proteins have recently been associated with other unique 
signal transduction pathways that involve proteins derived from 
the Drosophila Wingless (Wg) and the mouse Int-1 genes.133 The 
Wnt proteins are secreted cysteine-rich glycosylated proteins that 
can control cell proliferation, differentiation, survival and tumori-
genesis.59,155  More  than  eighty  target  genes  of  Wnt  signaling 
pathways have been demonstrated in human, mouse, Drosophila, 
Xenopus and zebrafish. These genes are present in several cellular 
populations, such as neurons, cardiomyocytes, endothelial cells, 
cancer cells and pre-adipocytes.84 At least 19 of 24 Wnt genes that 
express Wnt proteins have been identified in the human.59,155,156
The canonical Wnt pathway controls target gene transcription 
through β-catenin.59,155 It is the β-catenin pathway that appears 
to tie FoxO proteins and Wnt signaling together.21 For example,   126 Oxidative Medicine and Cellular Longevity 2009; Vol. 2 Issue 3
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of biological outcomes during FoxO protein involvement may not 
be consistently known and may be influenced by multiple param-
eters such as tissue characteristics, cellular metabolic state and the 
age of an individual. These observations argue for further robust 
basic and clinical studies to further comprehend the potential fruits 
and failures for FoxO proteins as novel therapeutic strategies.
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